Amycretin
Early-stage investigational unimolecular GLP-1 and amylin receptor co-agonist from Novo Nordisk, generating attention for very large weight loss in early trials, available in both oral and injectable forms.
01 Overview
Amycretin is a single-molecule co-agonist of the GLP-1 and amylin receptors under development by Novo Nordisk. By combining incretin and amylin signalling, it aims to exceed the weight loss of current agents. It has been studied as both an oral tablet and a subcutaneous injection.
Early Phase 1/2 data have shown striking weight loss over relatively short periods, drawing considerable interest. However, the evidence base is very early, participant numbers small, and long-term efficacy and safety remain unknown.
02 Mechanism
Unimolecular co-agonism of GLP-1 and amylin receptors, combining incretin-driven appetite suppression with amylin-mediated satiety and slowed gastric emptying.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Trial dose (oral) | 3–100 mg/day | Oral | Oral formulation studied in Phase 1 |
| Trial dose (injectable) | 5–60 mg/wk | SubQ | Wide dose range explored in early trials |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Weight lossLarge short-term weight loss in early-phase trials. | ~13-22% over weeks | Clinical | |
| Appetite suppressionCombined incretin/amylin satiety effect. | Marked | Clinical |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Gastrointestinal effectsNausea and vomiting, dominant in early trials. | Moderate | Very common | Clinical | |
| Reduced appetite / under-eatingStrong appetite suppression can lead to inadequate intake. | Mild | Very common | Clinical |